Jan 8 (Reuters) - MoonLake Immunotherapeutics :
* MOONLAKE INITIATES THREE NEW CLINICAL TRIALS AND FURTHER EXPANDS THE PORTFOLIO OF INDICATIONS FOR THE NANOBODY® SONELOKIMAB
* MOONLAKE IMMUNOTHERAPEUTICS - PHASE 2 AND 3 DATA READ-OUTS EXPECTED IN 2025 AND 2026
* MOONLAKE IMMUNOTHERAPEUTICS - RUNNING SEVEN TRIALS IN 2025
* MOONLAKE IMMUNOTHERAPEUTICS - TOPLINE PRIMARY ENDPOINT READOUT EXPECTED IN 2025
* MOONLAKE IMMUNOTHERAPEUTICS - PRIMARY ENDPOINT OF S-OLARIS TRIAL IS CHANGE IN 18F-NAF UPTAKE
Source text: Further company coverage:
((Reuters.Brief@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.